Skip to content
< Back to blog

Devyser winner of Swecare Export Awards 2023


News | April 27, 2023

Devyser has been awarded the Swecare Export Award 2023. The prize is awarded to companies that "with creativity, commitment and scope put Swedish innovation in health and healthcare on the world map". Ulf Klangby, deputy CEO and one of the company's founders, received the award from the Minister of Social Affairs Jacob Forssmed at a ceremony in Stockholm earlier today.

Swecare is a foundation that has the Swedish Ministry of Social Affair´s mission to create platforms for companies and organizations within the Swedish life science sector with the aim of contributing to increased exports of Swedish products, services, and knowledge. Swecare was established in 1978 by the Swedish government, the then Export Council, and healthcare industry representatives.

The “Swecare Export Award” has been awarded annually for more than 10 years. Of five nominated companies, Devyser was named this year's prestigious award winner. The jury consists of representatives from the life science industry and the Swedish government.

The jury´s motivation to the Swecare Export Award 2023:

“The winner is a pioneer in advanced genetic testing, DNA diagnostics. The company is at the forefront of research in one of the areas that has the potential to revolutionize healthcare by enabling to identify and predict diseases early. Through the goal that every patient should receive a correct diagnosis in the shortest possible time, they contribute to a development with a focus on the patient and care provider with regards to sustainability and resources. From the beginning a research company that from the head office in Hägersten developed 29 different products that are now available in 50 countries. With intensive export investments in recent years, they have made a fantastic growth journey with great sales successes, where 92 percent of total sales are made up of export income”.

“We are incredibly proud to be recognized with this fine award”, comments Fredrik Alpsten, CEO of Devyser. "We have had strong international growth in recent years, especially in Europe and Asia. Our investment in expanding direct sales in key markets has been highly successful. Now our focus is on the North American market. In June, we will inaugurate our new laboratory in Atlanta, Georgia, and earlier this week we presented a collaboration agreement with Thermo Fisher Scientific, an American company and world leader in the diagnostics industry. Through this partnership Thermo Fisher Scientific will market and sell, under combined brands, Devyser's unique post-transplant follow-up NGS products in the US, Canada, and Europe, which means more patients can access better transplant care.”

For more information, please contact:

Fredrik Alpsten, CEO
Phone: + 46 70 667 31 06 

About Devyser

Devyser develops, produces, and sells genetic testing kits and services to clinical laboratories in more than 50 countries. The products are used for advanced DNA testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a broad range of genetic diseases, and post-transplant patient follow-up. Devyser’s patented easy-to-use single-tube test simplify genetic testing processes, minimize hands-on time, and deliver rapid, accurate, and trusted results. Our aim is to ensure every patient gets a correct diagnosis in the shortest possible time.

Devyser was founded in 2004 and is based in Stockholm, Sweden. We have 8 own sales offices in Europe and the US where we also have a service lab in Atlanta, Georgia. In August 2022 we received certification for our quality management system and Devyser Compact under the new comprehensive European IVD Regulation. 
Devyser’s shares are listed on Nasdaq First North Premium Growth Market (ticker: DVYSR). The company’s Certified Adviser is Redeye AB. 



Contact an expert at Devyser

If you have a question, feel free to send us a message. One of our team members will get in touch with you as soon as possible.

Contact us